Skip to main content
SpringerLink
Log in

Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome

  • Original Article
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

We compared, in a randomized controlled trial, the efficacy of a regimen based on intravenous (i.v.) cyclophosphamide therapy with a combination of i.v. dexamethasone and oral cyclophosphamide therapy in inducing remission in patients with steroid-resistant nephrotic syndrome (SRNS). During April 2001 to December 2003, 52 consecutive patients with idiopathic SRNS, normal renal function and renal histology findings showing minimal change disease, focal segmental glomerulosclerosis or mesangioproliferative glomerulonephritis were enrolled into the study. Patients in group I received i.v. injection of cyclophosphamide once a month for 6 months and prednisolone on alternate days. Those in group II received i.v. treatment with dexamethasone (initially on alternate days, later fortnightly and monthly; total 14 doses), oral cyclophosphamide therapy (for 3 months) and prednisolone on alternate days. Data from 49 patients (26 in group I, 23 in group II) were analyzed; their clinical and biochemical features were similar at inclusion. Following treatment, complete remission was seen in 53.8% and 47.8% patients in groups I and II, respectively (P = 0.6). Long-term follow up showed favorable outcome in 14 (53.8%) patients in group I, and 9 (39.1%) in group II. Chief adverse effects, including cushingoid features and serious infections, were similar in both groups. Patients receiving i.v. dexamethasone therapy commonly showed hypertension and hypokalemia, while vomiting and reversible alopecia occurred in those receiving i.v. treatment with cyclophosphamide. In patients with SRNS, the efficacy of treatment intravenously with cyclophosphamide and orally with prednisolone was similar to the combination of dexamethasone intravenously, orally administered cyclophosphamide and prednisolone.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Eddy AA, Symons JM (2003) Nephrotic syndrome in childhood. Lancet 362:629–639

    Article  Google Scholar 

  2. Niaudet P, Fuchshuber A, Gagnadoux MF, Habib R, Broyer M (1997) Cyclosporine in the therapy of steroid-resistant idiopathic nephrotic syndrome. Kidney Int Suppl 58:S85–S90

    CAS  PubMed  Google Scholar 

  3. Habashy D, Hodson EM, Craig JC (2003) Interventions for steroid-resistant nephrotic syndrome: a systematic review. Pediatr Nephrol 18:906–912

    Article  Google Scholar 

  4. Bhimma R, Adhikari M, Asharam K, Connolly C (2006) Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 26:544–551

    Article  CAS  Google Scholar 

  5. Tune BM, Kirpekar R, Sibley RK, Reznik VM, Griswold WR, Mendoza SA (1995) Intravenous methylprednisolone and oral alkylating agent therapy of prednisone-resistant pediatric focal segmental glomerulosclerosis: a long-term follow-up. Clin Nephrol 43:84–88

    CAS  Google Scholar 

  6. Tune BM, Lieberman E, Mendoza SA (1996) Steroid resistant focal segmental glomerulosclerosis; a treatable disease. Pediatr Nephrol 10:772–778

    Article  CAS  Google Scholar 

  7. Rennert WP, Kala UK, Jacobs D, Goetsch S, Verhaart S (1999) Pulse cyclophosphamide for steroid-resistant focal segmental glomerulosclerosis. Pediatr Nephrol 13:113–116

    Article  CAS  Google Scholar 

  8. Gulati S, Kher V (2000) Intravenous pulse cyclophosphamide—a new regime for steroid resistant focal segmental glomerulosclerosis. Indian Pediatr 37:141–148

    CAS  Google Scholar 

  9. Hari P, Bagga A, Jindal N, Srivastava RN (2001) Treatment of focal glomerulosclerosis with pulse steroids and oral cyclophosphamide. Pediatr Nephrol 16:901–905

    Article  CAS  Google Scholar 

  10. Hari P, Bagga A, Mantan M (2004) Short term efficacy of intravenous dexamethasone and methylprednisolone therapy in steroid resistant nephrotic syndrome. Indian Pediatr 41:993–1000

    PubMed  Google Scholar 

  11. Bajpai A, Bagga A, Hari P, Dinda A, Srivastava RN (2003) Intravenous cyclophosphamide in steroid-resistant nephrotic syndrome. Pediatr Nephrol 18:351–356

    Article  Google Scholar 

  12. Schwartz GJ, Haycock GB, Edelman CM, Spitzer A (1976) A simple measure of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263

    CAS  Google Scholar 

  13. Indian Pediatric Nephrology Group, Indian Academy of Pediatrics (2001) Consensus statement on management of steroid sensitive nephrotic syndrome. Indian Pediatr 38:975–986

    Google Scholar 

  14. National Center for Health Statistics (1978) Centers for Disease Control NCHS growth curves for children: birth–18 years. Washington DC: US Government Printing Office (Series 11, 165. DHEW publication (PHS) 78 1650)

  15. Adhikari M, Bhimma R, Coovadia HM (1997) Intensive pulse therapies for focal glomerulosclerosis in South African children. Pediatr Nephrol 11:423–8

    Article  CAS  Google Scholar 

  16. Elhence R, Gulati S, Kher V, Gupta A, Sharma RK (1994) Intravenous pulse cyclophosphamide—a new regime for steroid resistant minimal change nephrotic syndrome. Pediatr Nephrol 8:1–3

    CAS  Google Scholar 

  17. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr (1997) Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 8:769–776

    CAS  Google Scholar 

  18. Tarshish P, Tobin JN, Bernstein J, Edelman CM Jr (1996) Cyclophosphamide does not benefit patients with focal segmental glomerulosclerosis: a report of the International Study of Kidney Diseases in Children. Pediatr Nephrol 10:590–593

    Article  CAS  Google Scholar 

  19. Bhimma R, Adhikari M, Asharam K (2006) Steroid-resistant nephrotic syndrome: the influence of race on cyclophosphamide sensitivity. Pediatr Nephrol 21:1847–1853

    Article  Google Scholar 

  20. Ingulli E, Tejani A (1991) Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 5:393–397

    Article  CAS  Google Scholar 

  21. Boyer O, Moulder JK, Somers MJG (2007) Focal and segmental glomerulosclerosis in children: a longitudinal assessment. Pediatr Nephrol 22:1159–1166

    Article  Google Scholar 

  22. Gulati S, Kher V, Sharma RK, Gupta A (1994) Steroid response pattern in Indian children with nephrotic syndrome. Acta Paediatr 83:530–533

    Article  CAS  Google Scholar 

  23. Mongeau JG, Corneille L, Robitaille P, O’ Regan S, Pelletier P (1981) Primary nephrosis in childhood associated with focal segmental glomerulosclerosis: is long term prognosis that severe? Kidney Int 20:743–746

    Article  CAS  Google Scholar 

  24. Hiraoka M, Tsukahara H, Haruki S, Hayashi S, Takeda N, Miyagawa K, Okuhara K, Suehiro F, Ohshima Y, Mayumi M (2000) Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome The West Japan Cooperative Study of Kidney Disease in Children. Kidney Int 58:1247–1252

    Article  CAS  Google Scholar 

  25. Constantinescu AR, Shah HB, Foote EF, Weiss LS (2000) Predicting first year relapses in children with nephrotic syndrome. Pediatrics 105:492–495

    Article  CAS  Google Scholar 

  26. Latta K, Von Schnakenburg C, Ehrich JH (2001) A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children. Pediatr Nephrol 16:271–282

    Article  CAS  Google Scholar 

  27. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N (2007) Cyclosporine in idiopathic glomerular disease associated with the nephritic syndrome: workshop recommendations. Kidney Int 72:1429–1447

    Article  CAS  Google Scholar 

  28. Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP (2008) Tacrolimus: a new therapy for steroid resistant nephrotic syndrome in children. Nephrol Dial Transplant 23:910–913

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Maulana Azad Medical College, Delhi, India

    Mukta Mantan

  2. Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India

    Chenni S. Sriram, Pankaj Hari & Arvind Bagga

  3. Department of Pathology, All India Institute of Medical Sciences, New Delhi, India

    Amit Dinda

Authors
  1. Mukta Mantan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chenni S. Sriram
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pankaj Hari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amit Dinda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arvind Bagga
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arvind Bagga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mantan, M., Sriram, C.S., Hari, P. et al. Efficacy of intravenous pulse cyclophosphamide treatment versus combination of intravenous dexamethasone and oral cyclophosphamide treatment in steroid-resistant nephrotic syndrome. Pediatr Nephrol 23, 1495–1502 (2008). https://doi.org/10.1007/s00467-008-0860-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-008-0860-8

Keywords

Search

Navigation